ApprovedFDA approval

Etcamah (camizestrant)

AstraZeneca (AZN)

Marketer take

Labeled for switching when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 therapy, which makes mutation testing during first-line treatment the core message, and it competes with Orserdu and Veppanu in ESR1-mutated disease.

Sponsor company
AstraZeneca (AZN)
Indication
To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
Therapeutic area
Oncology
Event
FDA approval
Date
Sep 4, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move